TY - JOUR
T1 - Eosinophilic esophagitis
T2 - A clinicopathological review
AU - Philpott, Hamish
AU - Nandurkar, Sanjay
AU - Thien, Francis
AU - Gibson, Peter R.
AU - Royce, Simon G.
PY - 2015
Y1 - 2015
N2 - Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.
AB - Eosinophilic esophagitis (EoE) is considered to be a chronic antigen-driven disease whereby food and/or aeroallergens induce a chronic inflammatory infiltrate in the esophagus, resulting in pathological hyperplasia of the epithelia and muscular layers, and fibrosis of the lamina propria (referred to collectively as remodelling) and the symptoms of dysphagia and food impaction. EoE shares features with other atopic conditions of asthma and atopic dermatitis, such as a TH2 cytokine milieu and a mixed inflammatory infiltrate of eosinophils, mast cells and lymphocytes. Relatively distinct features include the strong male predominance amongst adult patients, and the expression of the eosinophil chemokine eotaxin 3. Current first line treatments such as strict dietary modification and corticosteroids fail many patients. Looking forward, clarification of distinct genotype/phenotype associations, determining the reversibility of remodelling following treatment, and the development of new pharmacotherapies that target fibrotic pathways (as opposed to eosinophilic inflammation per se) or specifically improve barrier integrity appear relevant.
KW - Allergy
KW - Diet
KW - Dysphagia
KW - Eosinophil
KW - Esophagitis
KW - Remodelling
UR - http://www.scopus.com/inward/record.url?scp=84921297863&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2014.09.001
DO - 10.1016/j.pharmthera.2014.09.001
M3 - Article
SN - 0163-7258
VL - 146
SP - 12
EP - 22
JO - Pharmacology & Therapeutics
JF - Pharmacology & Therapeutics
ER -